(Q36561615)

14 August 2017

1 reference

title

What brown cannot do for you. (English)

1 reference

14 August 2017

David L Rimm

1

1 reference

14 August 2017

language of work or name

1 reference

1 August 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

24

1 reference

14 August 2017

issue

8

1 reference

14 August 2017

page(s)

914-916

1 reference

The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-914

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-914

Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-914

Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-914

Double autoimmunostaining with glycine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-914

Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-914

Automated subcellular localization and quantification of protein expression in tissue microarrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-914

A gene-expression signature as a predictor of survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-914

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-914

A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-914

Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-914

Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-914

The relevance of antibody concentration to the immunohistological quantification of cell proliferation-associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-914

7 January 2021

p53 in tumour pathology: can we trust immunohistochemistry?--Revisited!

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-914

7 January 2021

Endocrine therapy of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-914

7 January 2021

Histochemical assay of estrogen and progesterone receptors in breast cancer: Correlation with biochemical assays and patients' response to endocrine therapies

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-914

7 January 2021

Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-914

7 January 2021

Estrogen receptor testing of breast cancer in current clinical practice: what's the question?

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-914

7 January 2021

Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab

1 reference

https://api.crossref.org/works/10.1038%2FNBT0806-914

7 January 2021

Identifiers

DOI

10.1038/NBT0806-914

1 reference

14 August 2017

1 reference